Teva sues two Indian generics over Huntington’s treatment

Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Generics

Generics win anti-pay-for-delay bill challenge

14 December 2021 The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.

Big Pharma

Teva settles patent dispute with Aurobindo

13 June 2022 Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.

More on this story

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Generics

Generics win anti-pay-for-delay bill challenge

Big Pharma

Teva settles patent dispute with Aurobindo

13 June 2022 Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.

More on this story

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Generics

Generics win anti-pay-for-delay bill challenge

Big Pharma

Teva settles patent dispute with Aurobindo

13 June 2022 Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.